shockwave
ivl
meets
safety
effectiveness
endpoints
coronary
pivotal
ide
study
santa
clara
globe
newswire
shockwave
medical
nasdaq
swav
pioneer
development
commercialization
intravascular
lithotripsy
ivl
treat
severely
calcified
cardiovascular
disease
announced
today
coronary
investigational
device
exemption
ide
study
disrupt
cad
iii
met
primary
safety
effectiveness
endpoints
results
presented
earlier
today
clinical
session
virtual
transcatheter
cardiovascular
therapeutics
conference
tct
connect
published
simultaneously
journal
american
college
cardiology
jacc
disrupt
cad
iii
prospective
multicenter
global
ide
study
investigating
shockwave
coronary
ivl
system
de
novo
calcified
stenotic
coronary
arteries
prior
stenting
study
enrolled
patients
sites
united
states
france
germany
united
kingdom
including
patients
optical
coherence
tomography
oct
data
adjudicated
cad
iii
represents
one
challenging
series
calcified
lesions
ever
treated
ide
lesions
determined
core
lab
severely
calcified
average
calcium
lesion
length
average
calcium
arc
degrees
thickness
site
maximum
calcification
measured
correlation
calcium
severity
poor
percutaneous
coronary
intervention
outcomes
well
established
challenge
face
daily
basis
cath
lab
given
severity
lesion
vessel
calcium
present
cad
iii
makes
findings
study
even
significant
noteworthy
said
dean
kereiakes
facc
fscai
medical
director
christ
hospital
heart
vascular
center
christ
hospital
research
institute
professor
clinical
medicine
ohio
state
university
investigator
disrupt
cad
iii
high
rate
procedural
success
combined
low
rate
major
adverse
cardiovascular
events
cad
iii
met
performance
goals
also
surpassed
expectations
disrupt
cad
iii
based
predicate
study
orbit
ii
ide
study
orbital
atherectomy
develop
performance
goals
would
allow
fda
evaluate
safety
effectiveness
ivl
single
arm
study
coronary
ivl
met
safety
effectiveness
goals
disrupt
cad
iii
freedom
mace
rate
percent
p
procedural
success
rate
percent
p
respectively
coronary
ivl
prior
stent
implantation
well
tolerated
low
rate
major
clinical
angiographic
complications
individual
components
percent
mace
rate
included
low
rates
cardiac
death
percent
myocardial
infarction
percent
target
vessel
revascularization
percent
days
following
index
procedure
freedom
serious
angiographic
complication
following
ivl
delivery
point
procedure
percent
percent
respectively
coronary
ivl
showed
low
risk
complications
including
perforation
percent
major
dissection
percent
abrupt
closure
percent
slow
flow
reflow
percent
end
procedure
cad
iii
demonstrated
effectiveness
coronary
ivl
treating
calcium
large
lumen
gains
facilitated
stent
delivery
primary
effectiveness
endpoint
procedural
success
percent
individual
endpoints
included
successful
stent
delivery
percent
patients
residual
stenosis
less
percent
cases
mace
percent
patients
despite
marked
severity
calcified
lesions
treated
ivl
able
cross
deliver
therapy
percent
lesions
reflected
successful
stent
delivery
percent
time
end
procedure
ivl
resulted
average
acute
gain
average
final
residual
stenosis
percent
presentation
publication
cad
iii
study
significant
milestone
investigators
company
also
interventional
cardiology
community
large
said
keith
dawkins
chief
medical
officer
shockwave
medical
cad
iii
sets
new
benchmark
treatment
complex
coronary
calcification
want
commend
many
physicians
clinical
coordinators
diligent
work
evaluating
novel
shockwave
coronary
ivl
catheters
commercially
available
treatment
de
novo
coronary
artery
disease
europe
select
geographies
limited
investigational
use
united
states
shockwave
medical
shockwave
focused
developing
commercializing
products
intended
transform
way
calcified
cardiovascular
disease
treated
shockwave
aims
establish
new
standard
care
interventional
treatment
atherosclerotic
cardiovascular
disease
differentiated
proprietary
local
delivery
sonic
pressure
waves
treatment
calcified
plaque
company
refers
intravascular
lithotripsy
ivl
ivl
minimally
invasive
safe
way
significantly
improve
patient
outcomes
view
animation
ivl
procedure
information
visit
statements
press
release
contains
statements
relating
expectations
projections
beliefs
prospects
including
statements
regarding
product
development
outlook
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
statements
words
may
might
expects
plans
anticipates
believes
estimates
predicts
potential
continue
similar
expressions
negative
terms
statements
subject
risks
uncertainties
assumptions
us
guarantees
future
performance
cautioned
place
undue
reliance
statements
statements
contained
press
release
may
include
limited
statements
impact
pandemic
operations
financial
results
liquidity
capital
resources
including
sales
expenses
supply
chain
manufacturing
research
development
activities
clinical
trials
employees
ability
design
develop
manufacture
market
innovative
products
treat
patients
challenging
medical
conditions
particularly
peripheral
artery
disease
coronary
artery
disease
aortic
stenosis
expected
future
growth
including
growth
international
sales
size
growth
potential
markets
products
ability
serve
markets
rate
degree
market
acceptance
products
coverage
reimbursement
procedures
performed
using
products
performance
third
parties
connection
development
products
including
suppliers
regulatory
developments
united
states
foreign
countries
ability
obtain
maintain
regulatory
approval
clearance
products
expected
timelines
plans
research
develop
commercialize
products
approved
cleared
product
ability
scale
organizational
culture
cooperative
product
development
commercial
execution
development
regulatory
approval
efficacy
commercialization
competing
products
loss
key
scientific
management
personnel
expectations
regarding
period
qualify
emerging
growth
company
jobs
act
ability
develop
maintain
corporate
infrastructure
including
internal
controls
financial
performance
capital
requirements
expectations
regarding
ability
obtain
maintain
intellectual
property
protection
products
well
ability
operate
business
without
infringing
intellectual
property
rights
others
statements
predictions
based
current
expectations
projections
future
events
important
factors
could
cause
actual
results
level
activity
performance
achievements
differ
materially
results
level
activity
performance
achievements
expressed
implied
statements
factors
well
others
discussed
filings
securities
exchange
commission
sec
including
part
item
ia
risk
factors
recent
annual
report
form
filed
sec
periodic
reports
filed
sec
statements
make
based
current
expectations
estimates
assumptions
regarding
future
events
applicable
dates
statements
may
additional
risks
presently
aware
currently
believe
immaterial
could
adverse
impact
business
although
believe
expectations
reflected
statements
reasonable
guarantee
future
results
level
activity
performance
achievements
except
extent
required
law
undertake
update
statements
date
press
release
conform
statements
actual
results
revised
expectations
